| Revision as of 20:16, 11 March 2007 editArcadian (talk | contribs)163,050 edits {{Antidepressants}}, added reference, templated existing ref← Previous edit | Revision as of 21:37, 19 April 2007 edit undoJohner (talk | contribs)1,242 editsNo edit summaryNext edit → | ||
| Line 1: | Line 1: | ||
| '''Noradrenergic and specific serotonergic antidepressants''' (abbreviated: '''NaSSAs''') are a relatively new class of ]s.<ref>{{cite journal |author=Kent J |title=SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression |journal=Lancet |volume=355 |issue=9207 |pages=911-8 |year=2000 |pmid=10752718}}</ref> They are thought to |
'''Noradrenergic and specific serotonergic antidepressants''' (abbreviated: '''NaSSAs''') are a relatively new class of ]s.<ref>{{cite journal |author=Kent J |title=SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression |journal=Lancet |volume=355 |issue=9207 |pages=911-8 |year=2000 |pmid=10752718}}</ref> They are thought to work by blocking presynaptic alpha-2 ] that normally inhibit the release of the ]s ] (]) and ]. This results in increases in both noradrenergic and specific serotonergic transmission. | ||
| Examples of NaSSAs include: | Examples of NaSSAs include: | ||
Revision as of 21:37, 19 April 2007
Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to work by blocking presynaptic alpha-2 adrenergic receptors that normally inhibit the release of the neurotransmitters norepinephrine (noradrenaline) and serotonin. This results in increases in both noradrenergic and specific serotonergic transmission.
Examples of NaSSAs include:
- Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)
NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with Mirtazapine.
See also
References
- Kent J (2000). "SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression". Lancet. 355 (9207): 911–8. PMID 10752718.
- Fawcett J, Barkin R (1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". J Affect Disord. 51 (3): 267–85. PMID 10333982. link
 | This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |